This is sign-on Letter -- Against life + 70 year copyright term in the TPP. See end of letter for details on how to sign.
December 9, 2013
Dear TPP negotiators,
In a December 7-10 meeting in Singapore you will be asked to endorse a binding obligation to grant copyright protection for 70 years after the death of an author. We urge you to reject the life + 70 year term for copyright.
Rep. Zoe Lofgren (D-CA) Criticizes Copyright Provisions in Trans-Pacific Partnership Agreement (TPP)Submitted by Krista Cox on 7. December 2013 - 4:47
On December 5, 2013, Representative Zoe Lofgren (D-CA) participated in a press conference where she criticized the copyright provisions in the Trans-Pacific Partnership Agreement (TPP). In particular, she noted three specific concerns including exporting lengthy copyright term, restrictions on copyright limitations and exceptions, and locking in bad provisions on technological protection measures (TPMs). The full press release is reprinted below:
Rep. Zoe Lofgren on Emerging & Controversial Trans Pacific Partnership (TPP) Trade Treaty
Professor Joseph Stiglitz has written an open letter to the TPP negotiators, asking that they resist proposals to weaken consumer rights in intellectual property. The letter identifies 12 specific "grave risks" in the IP Chapter, and calls upon negotiators to publish the investor state dispute resolution text.
In a 6 December 2013 letter, Representative Henry Waxman wrote to USTR Ambassador Michael Froman opposing USTR's proposal of a term of 12 years of exclusivity for biologics in the Trans Pacific Partnership (TPP). The letter notes,
[w]hile I have worked closely with Senator Hatch on important health issues, including the generic drug law that we co-authored in 1984, I strongly disagreed that the United States should be proposing twelve years of exclusivity.
USTR recently asked KEI if there were areas in the IP Chapter where we approved of the positions taken by USTR, and the answer is, yes. Given how critical we have been about the text, I will mention a few here.
USTR now "supports a more flexible approach under which partners could retain reasonable patent pre-grant opposition procedures." This is welcome, and useful.
In a word, MSF is disappointed.
Vatican criticizes Trans Pacific Partnership: Holy See statement to 9th WTO Ministerial Conference in BaliSubmitted by thiru on 5. December 2013 - 6:36
The 9th Ministerial Conference of the World Trade Organization (WTO) is taking place in Bali, Indonesia from 3-6 December 2013. At the Ministerial, H.E. Archbishop, Silvano M. Tomasi, Apostolic Nuncio, Permanent Observer of the Holy See to the United Nations and Other International Organizations in Geneva delivered a withering critique of the Trans Pacific Partnership and the Transatlantic Trade and Investment Partnership.
On November 28, 2013, I wrote a blog about the problems in using the World Bank's definition of high income, in the specifc context of a proposal by the United States to use this as a measure of which countries in the TPP should have lower standards for intellectual property rights on medical inventions. (See: http://www.keionline.org/node/1834).
Here a different metric is presented, based upon relative incomes, benchmarked against the five highest income countries in the TPP with a population of more than 1 million persons.
TPP: Senator Hatch to USTR, 12 years of IPR for Biologics test data, no restrictions on cross border data flowsSubmitted by James Love on 3. December 2013 - 14:08
In a December 2, 2013 letter, Senator Orrin Hatch wrote to USTR's Michael Froman, suggesting TPP exclude any countries that do not meet "high levels of ambition." According to Hatch, these high ambitions include agreeing to 12 years of exclusive rights for IPR in biologic drug test data, and the elimination of barriers to cross border data flows (a privacy issue). A copy of the Hatch letter is attached below.
The timing of the Hatch letter is designed to pressure countries meeting in Singapore on December 7-10 in the TPP negotiation, on these two contentious issues.
I missed this news earlier. Here is a report from IP-Watch:
3-5 December 2013: WHO Global Technical Consultative Meeting of Experts on Identification of Health R&D Demonstration ProjectsSubmitted by thiru on 2. December 2013 - 5:45
The World Health Organization (WHO) is convening a Global Technical Consultative Meeting of Experts on Identification of Health Research & Development Demonstration Projects from 3-5 December 2013.
The World Bank definition of "high income" has slipped, in relative terms, compared to high income countries in generalSubmitted by James Love on 28. November 2013 - 8:04
The United States has proposed that some (but no means all) IPR obligations involving medicines be modified for countries with incomes below the amount the World Bank defines as “high.” The threshold to be considered a high income country was $12,616 in per capita income for 2012, and is adjusted every year. In contrast, the US per capita income was $50,124 in 2012. (More data here)
Earlier this year, IP-Watch submitted two FOIA requests to USTR about the TPP negotiation. I am attaching two letters from USTR to IP-Watch about the FOIAs, and a file with 127 pages of emails between USTR and various industry lobbyists. (USTR provided KEI with copies of the files provdied to IP-Watch as part a separate KEI FOIA to USTR regarding communications involving the TPP).
A lot has clearly been withheld by USTR. According to USTR's June 19, 2013 letter to IP-Watch
KEI proposal for Antibiotics Innovation Funding Mechanism (AIFM), shortlisted for demonstration project by WHO's EURO regionSubmitted by James Love on 21. November 2013 - 10:29
The WHO is considering potential projects that will demonstrate the feasibility and benefits of open innovation models, delinkage of R&D costs and product prices, and innovative finance mechanisms. The process for selection began at the regional level, as each of six WHO regions was allowed to shortlist four projects that will be considered at a December 3-4, 2013 meeting of experts in Geneva, where the list will be narrowed again, and then considered by the WHO Executive Board in January 2014 and the WHO World Health Assembly in May 2014.
This note looks at the TPP, ACTA and TRIPS provisions on injunctions, and finds the TPP text unclear, as regards the possibility of exceptions to the obligation to make injunctions available in cases in of infringements. We have asked USTR and USPTO to clarify this issue.
The TRIPS text on injunctions reads as follows:
Section 2: civil and administrative procedures and remedies
Article 44 - Injunctions.